Method for prevention of suppurative-septic complications in patients with acute gangrenous cholecystitis in minimal access surgery
SUBSTANCE: ronkoleukin is administered in a dose of 500,000 units in a 0.9% physiological saline 20.0 ml. The prepared solution in an amount of 10.0 ml is administered into a round ligament of the liver through a catheter inserted under visual control. The rest amount of 10.0 ml is introduced into incisional wound edges on the 1st and 3rd postoperative days.
EFFECT: method provides stimulating local immunity in both the incisional wound, and the hepatoduodenal region ensured by a separate effect of cytokines on various groups of lymphatic nodes.
The invention relates to medicine, namely to surgery, and can be used in emergency abdominal surgery.
There is a method of treatment with interleukin-2 in advanced bacterial infections (German patent No. 3910011, AK 37/02, 1990). In this way the introduction of Il-2 intravenously, subcutaneously, intraperitoneally, intramuscularly leads to increased non-specific cellular response that will reduce the number of bacteria in the peritoneal cavity and reduction of endotoxins in the blood plasma. The method according to the patent may be used by injection of interleukin-2 in a dose of 1-3,5-106 U/kg in the postoperative period, the state after a serious injury, a common gram-positive and gram-negative infections, peritonitis.
The use of high doses of interleukin-2 can cause the development of toxic reactions and is very expensive.
The well-known "Method of adaptive immunotherapy for the treatment of patients with purulent-septic processes, patent RU No. 2098125 C1, A61K 38/20, AK 38/00, which emit mononuclear cells, cultured them with interleukin-2 and return parenteral patient, and available purulent cavity is washed with a solution containing a combination of cytokines obtained by culturing mononuclear cells with inteleukin-2.
This method has been applied t is like in combination with intravenous and not used as an independent method only local citicentre. The method of preparation of the complex autologous cytokines requires high technical support and material costs, as well as the time factor. When the washing solution is not absorbed and does not provide enough long-term impacts on local tissue, requires a higher concentration of the drug, frequency and duration of use, leading to increased treatment time.
The known method antibacterial prophylaxis of infectious complications in surgery of the liver, gall bladder and biliary tract. The antibiotic must be entered before skin incision, that is, until bacterial contamination, so that a bactericidal concentration was maintained in the tissues during the entire operating period. Antibacterial medication should be 10-15 minutes intravenous or for 30-60 minutes intramuscularly before skin incision. The drugs of choice are:
1. Cefazolin 1.2 g/
2. Cefuroxime 1.5 g/
3. Amoxicillin is known to be/clavulanate 1.2 g/C.
However, the operation performed for acute gangrenous cholecystitis, belongs to the class of "dirty" operations that involve the carrying out of antibacterial therapy. Abdominal surgical infection Ed. Savelyeva B.C., Gelfand BYR - M - 2011. S-85.
The disadvantage of this method is the fact, h is about to date, the majority of microorganisms, antibioticresistant and the use of antibiotics, for the prevention of septic complications, is less effective than the proposed method.
The closest is the way of antibacterial therapy through a catheter in the round ligament of the liver under visual and palpatory control in patients with acute destructive cholecystitis during the operation of the mini-access (Shevela A.I., Morozov V.V., Kuznetsov A.V. Antibacterial therapy through the round ligament of the liver in patients with acute cholecystitis during operations from mini-access // Fundamental research. - 2006. No. 1 - p.40-41).
The disadvantage of this method is a local antibiotic therapy in the upper floor of the abdominal cavity and prolonged standing of the catheter.
The present invention is improving the efficiency of the method of prophylaxis of septic complications in patients with acute gangrenous cholecystitis during the operation of the mini-access by enhancing specific immune response in the operating wound in the upper floor of the abdominal cavity.
This object is achieved by a method of prophylaxis of septic complications in patients with acute gangrenous cholecystitis during the operation of the mini-access, including the introduction of the drug in the round ligament of the liver through a catheter into it under visual control. Inject Roncoleukin dose of 500,000 IU per 20,0 ml physiologists the definition of the solution of sodium chloride 0,9%, with 10.0 ml of solution is injected into the catheter and 10.0 ml of the solution into the edges of the surgical wound in the 1st and 3rd day postoperative period.
The novelty of the invention:
- inject Roncoleukin dose of 500,000 IU per 20,0 ml of physiological solution of sodium chloride 0,9%;
to 10.0 ml of solution is injected into the catheter and 10.0 ml of the solution into the edges of the surgical wound in the 1st and 3rd day postoperative period.
This allows you to quickly create a higher concentration in areas of interest, which increases the efficiency of action of the drug. In addition, the introduction of Roncoleukin stimulates production of interleukin-2, which significantly improves local immunity.
The subcutaneous route of administration, in contrast to intravenous, intramuscular and the application allows you to quickly create a higher concentration of the drug in the area of interest, which considerably increases the efficiency of action. The drug is injected directly into the surgical wound, where and formed local immune response and increase the immunological reactivity, allowing you to more efficiently sanitize the source of the infection.
For the first time in surgical practice used combined Loco-regional therapy for the prevention of septic complications in patients with acute gangrenous cholecystitis during the operation of the mini-access.
Sosaku is of essential features can significantly increase local immunity, as in the area of the wound, and hepatoduodenal region, which greatly improves the prevention of the development of wound and intra-abdominal septic complications in acute gangrenous cholecystitis.
The method is as follows.
When performing cholecystectomy from mini-access, using the apparatus "mini-assistant" for acute gangrenous cholecystitis, after performing the main stage of the operation, on the middle line of the abdomen above the navel 1-2 cm and 1 cm to the right produce vcol needle perpendicular to the skin. The needle is injected deep, piercing the broad aponeurosis of the abdominal muscles until you feel a failure. Needle inside the round ligament of the liver, controlling the needle position visually. The lumen of the needle enter the conductor and establish a polyethylene catheter. Inject Roncoleukin dose of 500,000 IU per 20,0 ml of physiological solution of sodium chloride at 0.9%. 10.0 ml of solution is injected into the catheter and 10.0 ml of the solution into the edges of the surgical wound. Perform skin puncture needle at a distance of 1.0 cm from the incision and enter 5.0 solution in the subcutaneous tissue on each side in the 1st and 3rd day postoperative period.
Clinical example 1
Woman, 55 years old (case history 216) received emergency surgery Department at CCH 1 core 18.01.13 with a diagnosis of JCB. Acute calculate the cholecystitis.
Since the receipt was a complex conservative therapy of acute cholecystitis: infusion, antispasmodic therapy. Despite ongoing therapy, the patient remained without positive dynamics.
19.01.13 performed surgery: cholecystectomy from mini-access, catheterization of the round ligament of the liver. Installed intraoperative diagnosis: ECB. Acute gangrenous cholecystitis. Local serous peritonitis.
1st day after the operation, the moderate, moderate pain. The body temperature of 38.4°C.
The prepared solution of Roncoleukin dose 500000 database of 20.0 ml of physiological solution of sodium chloride at 0.9% was injected 10.0 ml in the catheter and 10.0 ml of the solution into the edges of the surgical wound. Perform skin puncture needle at a distance of 1.0 cm from the incision and enter 5.0 solution in the subcutaneous tissue on each side in the 1st and 3rd day postoperative period.
After the end of therapy according to the proposed method the patient's condition has improved, the temperature was normalized, improved appetite, the patient became active, due to cancellation pain abdominal pain syndrome is not worried. Laboratory tests: the normalization of leucoformula, ESR, ultrasound-control: accumulation of fluid in the bed of the gallbladder no. 26.01.13 patient was discharged in satisfactory condition on the preamble is Torno aftercare.
Thus, the method has allowed to prevent the development of septic complications.
The use of the proposed invention increases the efficiency of the method of prevention of septic complications in patients with acute gangrenous cholecystitis during the operation of the mini-access, by increasing the specific immune response in the operating wound in the upper floor of the abdominal cavity.
The way to prevent septic complications in patients with acute gangrenous cholecystitis during the operation of the mini-access, including the introduction of the drug in the round ligament of the liver through a catheter into it under visual control, characterized in that the injected Roncoleukin dose of 500,000 IU per 20,0 ml of physiological solution of sodium chloride at 0.9%, and 10.0 ml of solution is injected into the catheter and 10.0 ml of the solution into the edges of the surgical wound in the 1st and 3rd day postoperative period.
SUBSTANCE: invention relates to medicine, namely to surgery and gastroenterology, and can be applied in treatment of patients with acute gastroduodenal bleedings. For this purpose on the 2-nd - 3-rd day after stabilisation of hemostasis a monitor purification with rinsing water is carried out. Temperature of water constitutes 30-32°C, and an intracolonic pressure is 20-25 mm Hg. Adsorbent polyphepan is added into rinsing water in a dose 10 g per 1500 ml of chemically pure decontaminated water of drinking water supply. Speed of supply and exhaust of rinsing water constitutes 1.0-1.6 l/min.
EFFECT: method ensures fast recovery of peristalsis and temperature normalisation, induced by development of endotoxicosis, due to effective purification of intestine from products of blood decay and microbial insemination as a result of selection of optimal parameters of the monitor intestine purification and required adsorbent.
1 tbl, 2 ex
SUBSTANCE: feeding a medical solution is combined with an exposure to low-frequency ultrasound generated by a low-frequency ultrasonic cavitator that is AUZKh-100 PHOTEK apparatus. The medical solution is presented by a solution of metrogyl and dioxydine in ratio 5:1 or 1:1 respectively. The exposure involves feeding the solution at 0.2-0.5 ml/s. The cavitator is placed at 0.2-0.5 cm from a defect surface. First, the defect is exposed to an average-density ultrasonic flow of power 1.6-3 Wt/cm2 for 1-2 min. Then, the exposure is characterised by average-density ultrasonic power 3.1-8 Wt/cm2 for 4-10 min. The therapeutic course is 3-15 sessions every second day.
EFFECT: method provides the maximum mechanical debridement of the purulent-fibrinous impositions and the qualitative wound disinfection ensured by selecting the cavitation mode for specific drug preparations and deep penetration of the above drug preparations into the lesion.
3 cl, 1 ex
SUBSTANCE: invention refers to medicine, namely to therapy, purulent surgery, and may be used for treating chronic wounds. That is ensured by implementing the versions of the methods of treating chronic wounds involving removing a portion of necrotic or other devitalised tissue from the wound with healthy tissue coated with a solvated system of an extracellular polymeric substance. The above system contains an aqueous solution of an agent isolating metal ions, a surfactant and a buffer substance. An osmolarity of the solvated system makes from approximately 1000 to approximately 4000 mOsm of the dissolved substance per one litre. What is also presented is a device for treating the given pathology comprising a wound cleansing instrument, a container for the solvated system of the extracellular polymeric substance, and an aspirator. What is presented is a kit for care for the patients suffering chronic wounds, comprising a tray, a syringe, a vessel with the solvated system of the extracellular polymeric substance, and printed application instructions.
EFFECT: presented group of inventions provide the effective treatment of chronic wounds by introducing the solvated system of the extracellular polymeric substance biocompatible with healthy tissues containing the ingredients preventing the binding of polymer chains in the extracellular polymeric material of a biofilm matrix and promoting transferring them into the solution for more complete removal from the wound.
67 cl, 2 tbl, 1 ex, 3 dwg
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, particularly to traumatology, orthopaedis, maxillofacial surgery, dentistry, neurosurgery, namely to osteoplastic formulation of biocomposites for treating human bone diseases and injures, and can be used as a material fully degradable in the body and replaceable by new bone tissue, for bone cell regeneration, as a biological filler for bone tissue defects, as an osteoconductive and osteoinductive biological frame for bone tissue regeneration. The hardened biocomposite for bone defect replacement on the basis of calcium phosphate contains magnesium phosphate, calcium hydrophosphate, amino acid; calcium phosphate is biological hydroxyapatite in the following proportions, wt %: hydroxyapatite - 45-47, magnesium phosphate - 32-34, calcium hydrophosphate - 16-19, amino acid - 1-5, as a binding agent - casein.
EFFECT: implementing the expansion of the biocomposites for bone defect replacement and endoprosthesis fixation.
SUBSTANCE: invention refers to medicine, particularly coloproctology, and may be used for treating chronic anal fissure. The method involves an anal fissurectomy with a graduated sphincterotomy and a drug-induced therapy. A patient's preoperative psychoemotional status is assessed by questionnaire survey according to the Hospital Anxiety and Depression Scale (HADS). If the disorders have been shown by the questionnaire survey, namely 8-10 points "subclinical anxiety/depression" or 11 points and more "clinical anxiety/depression", a psychopharmaceutical therapy with Grandaxin or Tianeptine. The preparations are administered in common doses for 4 weeks.
EFFECT: method provides the effective treatment of the disease with comorbid psychoemotional disorders, exposure on the additional mechanisms of the anal fissure pathogenesis in this case.
SUBSTANCE: invention refers to medicine, more specifically to injectable bioresorbable compositions of biocomposite materials for treating human bone diseases and disorders as: a material able to be biodegradable in the body completely and to be replaced by new bone tissue for the purpose of bone cell regeneration, osteoconductive and osteoinductive biological support frame for bone tissue regeneration, applied in traumatology, orthopaedics, maxillofacial surgery, and neurosurgery. The injectable biocomposite material contains biological hydroxyapatite, calcium hydrophosphate, amino acid arginine, as well as phosphoprotein (casein) recovered from skim milk, and glutaric aldehyde as a hardener.
EFFECT: preparing the bioresorbable material having the biocompatibility and the pronounced osteoconductive and osteoinductive properties.
2 cl, 1 ex
SUBSTANCE: invention refers to medicine, specifically to physiotherapy, surgery. A method consists in conducting a course of pelotherapy by applications. The therapy is started within the first four weeks following a laparotomy. The therapy involves the sulphide mud applications on an anteriolateral abdominal wall. The sulphide mud temperature is 42° C. The application length is gradually increased from 10 to 20 minutes. The procedures are performed every second day. A minimum number of the applications is 10.
EFFECT: method reduces the peritoneal adhesions.
SUBSTANCE: invention relates to medicine, namely to anaesthesiology, resuscitation and urology, and can be applied for prevention of cardiovascular complications in patients with syndrome of endogenous intoxication against the background of acute purulent pyelonephritis in perioperative period. For this purpose reamberine 1.5% in dose 400 ml is introduced to patient from the moment of clinical diagnosis daily to the moment of performing operation. After that, in the process of operation, at the stage of kidney decapsulation infusion of reamberine in the same dose in combination with intravenous blood irradiation is realised, with duration constituting 25 minutes. After that, in post operational period reamberine infusion is continued in the same dose during 8 days. Simultaneously for 3 days after operation intravenous blood irradiation is realised. From the 4-th day of post-operative period for five days reamberine infusions 1 time per day are combined with transdermal laser irradiation of operated kidney projection with duration 10 minutes. Then, without stopping reamberine infusion, biologically active points, connected with heart meridian C1, C2, C3, C4, C5, C6, C7, C8, C9, sympathetic point of heart meridian V15, ear points AP19, AP21, AP60, AP100, AP105, AP115 are successively exposed to laser irradiation.
EFFECT: method ensures effective prevention of cardiovascular complications due to reduction of level of toxic action of products of peroxide oxidation of lipids on myocardium, which makes it possible to improve functional state of myocardium.
1 tbl, 1 ex
SUBSTANCE: invention refers to medicine. What is described is using the material for the purpose of neural dysfunction recovery with the above material containing a polysaccharide derivative hydrogel wherein 0.5 wt % of the aqueous solution contains a complex module in the amount of 1 to 1000 N/m2, while a loss factor makes 0.01 to 2.0 that is measured at angular velocity 10 rad/sec with using a dynamic viscoelasticity meter. The above material for neural dysfunction recovery may represent hydrogel injected with using a syringe and has an excellent body residence, and has a restorative effect on the damaged or degenerated nerve function.
EFFECT: preparing the material for neural dysfunction recovery.
19 cl, 6 dwg, 6 ex
SUBSTANCE: inventions relate to medicine, namely, to thoracic surgery, and can be applied for control of pneumostasis. For this purpose indicator substance is additionally introduced into breathing mixture in carrying out artificial lung ventilation (ALV). As such means sulfur hexafluoride in ratio 1:5000 is applied. Detection of indicator means and intensity of its leakage flow in real time mode is used to judge about presence and degree of microdefect in the area of sutured tissue.
EFFECT: group of inventions makes it possible to realise effective control of lung tissue, bronchus stump and tracheobronchial sutures impermeability.
2 cl, 2 ex
SUBSTANCE: invention refers to medicine, particularly anaesthesiology and resuscitation. With aided longitudinal ultrasound scanning, a vein is punctured with a needle. The needle is placed in a caudal direction in a point 1-1.5 cm below an apex of a triangle at 15° to skin surface. The triangle is formed by feet of thoracoclaviculomastoid muscle. A J-conductor attached to the needle is moved into a vein lumen immediately after wall puncture.
EFFECT: method enables reducing a risk of developing complications, providing higher safety ensured by needle visualisation during catheterisation, and rate thereby avoiding an aspiration test.
SUBSTANCE: inventions relate to field of medicine. Method includes obtaining before or during interference unit of image data for measured space of a particular patient by means of scanning device; segmentation of image data in accordance with regions of tissues for creation of medical image of each tissue region from tissue regions; obtaining electromagnetic or acoustic data for each tissue region; processing of electromagnetic or acoustic data for creation of electromagnetic or acoustic model for one or more tissue regions, covering modelling space, corresponding to measured region of a particular patient and region of catheter tracking. Model is used for prediction of electromagnetic or acoustic field within tissue regions; bringing modeled space into correspondence with space of catheter tracking; measurement of electromagnetic or acoustic field of catheter during interference for reference to predicted electromagnetic or acoustic field of model to determine errors of catheter tracking; and correction of catheter position during tracking for minimisation of errors of catheter tracking.
EFFECT: application of inventions will make it possible to improve catheter tracking.
8 cl, 1 dwg
SUBSTANCE: invention is related to medicine, in particular to surgery, oncology, gastroenterology and clinical pharmacology and may be used for intubation of thin bowels and intrabowel introduction of medicinal agents and food products to patients in early postoperational period after stomach removal in case of esophageal-thin bowel anastomosis. Multifeeder includes reservoir, batching device, which connected reservoir to probe made of soft plastic, rubber or silicon tube with external diametre of 2-50 mm, oxygen hose, impeller, reducer, and hollow stem with sealing plug, at the end of which there is a mixer. Reservoir is made in the form of thermostat and comprises outlet valve. Oxygen hose is connected via nozzle to body of impeller, which under action of pressure from oxygen stream rotates mixer. At the same time some oxygen arrives to reducer into hollow stem connected to it with cross radial holes, and from it goes to reservoir of thermostat and is mixed with mixture. Batching device is equipped with nozzle and nipple, outlet valve, timer and controller with arrow and vernier with division value of 1 ml. Outlet end of probe is coated with heat insulation material. Working end with length of 40 cm is made of cellulose waxed on two sides with thickness of 50 - 500 mm with longitudinal stiffening ribs along the whole length arranged on internal surface, is filled with gelatin. Out of free butt end of working part there is gelatin protruding in the form of hemisphere with diametre equal to external diametre of probe. Method for enteral introduction of medicines and food after surgery on stomach includes intraoperational introduction of probe-multifeeder into thin bowel through jejunostome, control over location of multifeeder probe with the help of ray-tracing methods of diagnostics, multiple daily infusion of food mixtures homogenised in mixer for 6-7 days through probe, and these mixtures contain sufficient amount of proteins, fats, carbohydrates, vitamins in liquid or semi-liquid state, analysis of introduction intensity and cessation of introduction in case of painful feelings in abdomen, or repeated liquid stool, working end of probe is inserted into stump of duodenum and is moved to its proximal end. Control over location and availability of mixture in duodenum stump is done with the help of ultrasound. Single-time dose of medicine and natural gastric juice in volume of 15-30 ml are additionally added to mixture and heated up to not more than 45°C. Homogenising of mixture is carried out continuously with the help of mixer that operates under action of oxygen stream at higher pressure, dosed and controlled supply of ready mixture into duodenum stump is started after gelatin melting. Volume of mixture needed for complete filling of duodenum stump filling, mixture evacuation from it is controlled. Interval of time required for complete evacuation is identified, and another introduction of mixture is done in portions in this volume with established time interval.
EFFECT: invention improves efficiency and safety of nutrition and treatment due to better quality of mixture preparation, increased accuracy of its introduction and dosing.
2 cl, 1 dwg, 1 ex
SUBSTANCE: invention relates to the field of biotechnology and medicine. Claimed is a method of treating Alzheimer's disease, associated with low production of IL-10. The method includes increase of IL-10 level in an individual by introduction of efficient quantity of IL-10 or a molecule, increasing IL-10 production. Beta-amyloid can be one version of such a molecule. The claimed group of inventions can be used in medicine.
EFFECT: claimed is application of IL-10 for obtaining medication for treatment or prevention of Alzheimer's disease.
7 cl, 6 dwg, 9 tbl, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, particularly to genetic engineering, and may be used in preparing drugs for hepatitis C. What has been offered is using a pegylated methionine-containing form of N-terminal truncated IL-29 variant with a substituted cysteine residue in a position corresponding to position 171 of an amino acid sequence of a wild-type mature protein expressed in a heterologous system in the form of high homogenous preparations when preparing a drug for hepatitis C.
EFFECT: invention may be used in preparing the drugs for hepatitis C.
3 cl, 37 tbl, 45 ex
SUBSTANCE: there are performed beam therapy, intracavitary therapy and chemotherapy. For 5-7 days before the beginning of the radiation, Colagel-Beta with 1 β-interleukin 20 ml is introduced into a vaginal tube daily. Each session of the intracavitary therapy is preceded by introducing Colegel with 5-fluoruracil 20-25 ml into an uterine cavity and exposed for 30-40 minutes. Besides, from the beginning of the beam therapy 40-50 minutes after the radiation session, sodium alginate gel 20 ml containing methyluracil, dimethyl sulphoxide and hydrocortisone are introduced into a rectum and a bladder in a therapeutically effective amount. 5-10 procedures are performed.
EFFECT: providing faster regression of the tumour, reducing the rate and severity of radiation injuries of the rectus and bladder adjacent with the uterus with no risk of severe systemic toxic manifestations, including in senior patients with comorbid inoperable diseases and extended tumours.
FIELD: veterinary medicine.
SUBSTANCE: 10 minutes prior to direct carrying out of lymphotropic and lymph-stimulating injections, furosemide is intramuscularly injected to an animal at a dose of 2 mg per 1 kg of weight. After that, the lymphotropic antibiotic therapy is carried out. Then the lymph-stimulating injection is carried - in the thickness of the interspinous ligament of the spine at the level L2-L6 the mixture is injected at a dose of 1 ml per 5 kg body weight of an animal, which consists of 32 IU Lydazum, 500 thousand IU Roncoleukinum, 4 ml of 2% lidocaine solution, and 5 ml of 40% glucose solution. The lymphotropic injections are carried out every 24 hours. The lymph-stimulating injections are carried out every 48 hours. In total 5 lymphotropic and 3 lymph-stimulating injections are carried out.
EFFECT: method enables to improve the efficiency of antibiotic therapy in case of mastitis, to reduce the adverse effect of antibiotics on animal body, to accelerate relief of inflammatory edema and excretion of toxic products of inflammation, to improve overall immune reactivity of body and to reduce the therapy time.
SUBSTANCE: invention relates to molecular pharmacology and particularly to a peptide which is an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound. The invention shows that when bound with an alpha subunit of the receptor (IL-15Rα) the peptide inhibits T cell proliferation induced by IL-15, tumour necrosis factor α (TNFα) induction caused by IL-15, and expression of IL-8 and IL-6 caused by IL-15Rα. The invention also relates to use of the peptide in treating pathologies where anomalous expression of IL-15 or IL-15Rα is associated with the course of a disease such as rheumatoid arthritis (AR) and prostate cancer.
EFFECT: obtaining an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound.
18 cl, 6 dwg, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical compositions for treating a microbial disorder in an individual. As an agent, the pharmaceutical compositions (formulations) contain an antimicrobial peptide (AMP) containing IL-22 with a preset amino acid sequence and a nucleotide sequence coding AMP, or a modulator thereof specified in a group consisting of IL-6, IL-18, IL-23, REG lα, REG Iβ, HIP/PAP, REG III, REG IV, RS and lymphotoxin (LF), or agonist IL-22 in an effective amount and a pharmaceutically acceptable carrier. Using agonist IL-22 in the compositions provides higher IL-22 expression and/or activity with the agonist specified in the group of polypeptide, nucleic acid, and antibody. The therapeutic compositions are applicable for the intravenous administration.
EFFECT: using the compositions according to the invention provides higher expression of the antimicrobial pectin representing REGIIIβ and/or REGIIIγ that provides the protection of the intestinal epithelial barrier integrity, induces healing of wounds caused by the microbial disorder.
29 cl, 28 dwg, 10 ex
SUBSTANCE: invention refers to medicine, namely oncology and pulmonology, and concerns treating lung cancer. The therapeutic procedure is preceded by lymphocyte sampling from patient's blood by lymphocytapheresis to prepare a leukocytic mass. Then the leukocytic mass 20 ml is activated by ronkoleukine at 1000 units per 1 ml by incubation in a thermostat and double centrifugation. After the supernatant has been poured out, the residual cell mass is reduced to 20 ml by normal saline. That is followed by X-ray assissted immune chemoembolisation. Fresh activated leukocytic mass 20 ml is first introduced into the bronchial artery through a coaxial system with a microcatheter. The suspension of the chemopreparation and embolysate is administered.
EFFECT: method provides the high anti-tumour effect which is characterised by tumour regression, prolonged recurrence-free interval, prolonged lifespan, as well as reduced polychemotherapy-induced secondary immunodeficiency, complex correction of cell and humoral factors of the immune homeostasis, reduced probability of developing bronchopulmonary pyoinflammatory complications.
SUBSTANCE: group of inventions refers to medicine, namely to infectious diseases and may be used for treating and preventing hepatitis C in an individual received no drug therapy while being infected or at a risk of infection. That is ensured by subcutaneous introduction of mPEG-propionaldehyde pegylated polypeptide 1.5-5.0 mcg/kg having molecular weight approximately 20 kDa. The polypeptide contains the amino acid residues 1-176 SEQ ID NO: 106. and is pegylated type III interferon.
EFFECT: group of inventions provides treating hepatitis C in the above group of patients and reducing the toxic effects of the drugs administered.
11 cl, 113 dwg, 18 tbl, 1 ex